Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Cardiovascular calcification in chronic kidney disease: Risk factors and effect of α-keto acid tablets

Ning Xiang¹ , Haijun Liao², Zichen Zhai², Jingwen Gong²

¹Department of Geriatrics, Affiliated Hospital of Guizhou Medical University, Guizhou 550004, China; ²Guizhou Medical University, Guizhou 550004, China.

For correspondence:- Ning Xiang Email: kan6mw@163.com

Accepted: 5 October 2021 Published: 30 November 2021

Citation: Xiang N, Liao H, Zhai Z, Gong J. Cardiovascular calcification in chronic kidney disease: Risk factors and effect of α-keto acid tablets. Trop J Pharm Res 2021; 20(11):2451-2457 doi: 10.4314/tjpr.v20i11.30

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of α-keto acid tablets, and risk factors for cardiovascular calcification in patients with chronic kidney disease (CKD).

Methods: A total of 128 CKD patients were enrolled in this study. They were randomly assigned to study and control groups, each with 64 patients. Control patients received symptomatic treatment, while the study group patients received α-keto acid tablets plus. Indices of cardiovascular calcification, blood lipids and mineral metabolism were determined in the 2 groups of patients and compared. Risk factors for cardiovascular calcification were also analyzed.

Results: After treatment, the two groups had decreased CACS scores and reduced serum FGF-23 levels, with lower values in patients in the study group. Levels of Klotho and fetuin-A were significantly elevated after treatment, with higher values observed in study group patients. The degree of cardiovascular calcification was markedly lower in study group than that in controls. There was no significant difference in blood Ca level between the control and study groups before and after treatment. Logistic multivariate analysis demonstrated that hyperlipidemia, hyperphosphatemia, hypercalcemia, hypertension and diabetes put patients at risk for cardiovascular calcification.

Conclusion: Compound α-keto acid tablets delay cardiovascular calcification in patients with CKD, and alleviate symptoms of related risk factors for cardiovascular calcification.

Keywords: Compound α-keto acid tablets, Chronic kidney disease, Cardiovascular calcification, Risk factors